Views: 0 Author: Site Editor Publish Time: 2025-07-08 Origin: Site
CAS No. 105462-24-6, also known as (2R,3S)-N-tert-Butoxycarbonyl-3-phenylisoserine, is a chiral intermediate widely used in the semi-synthesis of Docetaxel and other taxane-based chemotherapy agents. This compound represents the Boc-protected form of the Docetaxel side chain, critical for constructing the correct pharmacologically active structure.
This intermediate plays a significant role in producing oncology APIs, and due to its stereochemical specificity, it is subject to rigorous quality control and high-purity standards.
This compound is a key component in building the (2R,3S)-3-phenylisoserine side chain used in Docetaxel and Paclitaxel synthesis.
Only the (2R,3S) enantiomer is used, making chiral synthesis or resolution technologies essential in its production.
Used in cytotoxic drug development, particularly for breast, prostate, and lung cancer treatments.
Due to its role in producing potent APIs, the manufacturing process follows Good Manufacturing Practices (GMP) and high containment protocols.
This intermediate is used by API manufacturers, CDMOs, and formulation companies worldwide for anticancer therapies.
Location: Basel, Switzerland
Overview: Lonza is a global leader in oncology-focused CDMO services and produces taxane intermediates like CAS 105462-24-6 at commercial scale.
Specialty: High-containment synthesis of chiral and cytotoxic intermediates.
Location: Plankstadt, Germany
Overview: CordenPharma supports integrated taxane intermediate development and custom synthesis under GMP conditions.
Specialty: Oncology CDMO services, including advanced taxane building blocks.
Location: Changzhou City, Jiangsu Province, China
Overview: Eastfine supplies CAS 105462-24-6 with full stereochemical precision, backed by regulatory support, competitive pricing, and reliable global shipping.
Specialty: High-purity taxane intermediates with strict quality control and strong export capacity.
Location: Milan, Italy
Overview: Dipharma manufactures cytotoxic and oncology intermediates, including Boc-protected isoserines for Docetaxel APIs.
Specialty: EU-GMP production and advanced chiral compound synthesis.
Location: Newcastle, United Kingdom
Overview: Sterling focuses on high-potency and high-containment intermediates for cancer drug development, including taxane side-chain compounds.
Specialty: Safe and scalable production of potent intermediates under regulatory compliance.
Location: Raubling, Germany
Overview: PharmaZell offers commercial-scale taxane intermediates for generic and branded oncology products.
Specialty: Sustainable and scalable production with a focus on semi-synthetic APIs.
Location: Beuvry-la-Forêt, France
Overview: Minakem provides high-purity cytotoxic intermediates for complex small molecules like Docetaxel and derivatives.
Specialty: Fully integrated development and GMP manufacturing.
Location: Bubendorf, Switzerland
Overview: Bachem supplies enantiomerically pure intermediates for oncology APIs, including protected isoserine derivatives.
Specialty: Chiral synthesis and regulatory-ready documentation.
Location: Craigavon, Northern Ireland
Overview: Almac offers GMP synthesis and scale-up of taxane intermediates, with short lead times and global delivery.
Specialty: Oncology intermediates for clinical and commercial supply.
Location: Zurich, Switzerland
Overview: VIO specializes in designing and producing functionalized side-chain intermediates used in anticancer API synthesis.
Specialty: Custom synthesis of Docetaxel side-chain precursors with full regulatory support.
With Docetaxel being a widely used chemotherapy agent, demand for CAS 105462-24-6 continues to rise from generic API producers.
Manufacturers are improving enantiomeric excess and reducing waste through enzymatic resolution and asymmetric synthesis.
Given its cytotoxic application, companies are investing in containment technologies to protect operators and ensure GMP compliance.
More pharmaceutical companies are turning to specialized CDMOs for advanced intermediates rather than producing in-house.
Authorities are tightening expectations for intermediate traceability, pushing companies to adopt digital batch records and enhanced QA systems.
CAS No. 105462-24-6 is a critical intermediate for Docetaxel and other taxane-based cancer drugs. As the global need for oncology APIs grows, especially in generic and biosimilar markets, reliable manufacturers like Eastfine, Lonza, Sterling, and CordenPharma are ensuring safe, compliant, and cost-effective production of this essential building block.
Its role in producing life-saving chemotherapy treatments underscores the importance of chiral precision, regulatory alignment, and scalable production in today’s pharmaceutical landscape.
简体中文